期刊
FRONTIERS IN CARDIOVASCULAR MEDICINE
卷 5, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fcvm.2018.00147
关键词
engineered myocardium; cardiovascular tissue engineering; co-culture; cardiomyocyte; endothelial cell; fibroblast; stem cell
资金
- US National Institutes of Health [R01 HL127113, R01HL142718]
- Department of Veterans Affairs [1I01BX002310]
- California Institute for Regenerative Medicine [10603]
Cardiovascular disease is a leading cause of death in the US and many countries worldwide. Current cell-based clinical trials to restore cardiomyocyte (CM) health by local delivery of cells have shown only moderate benefit in improving cardiac pumping capacity. CMs have highly organized physiological structure and interact dynamically with non-CM populations, including endothelial cells and fibroblasts. Within engineered myocardial tissue, non-CM populations play an important role in CM survival and function, in part by secreting paracrine factors and cell-cell interactions. In this review, we summarize the progress of engineering myocardial tissue with pre-formed physiological multicellular organization, and present the challenges toward clinical translation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据